Lotus Pharmaceutical, EF Biotech, and Hualian Tzu Chi Hospital to Form Alliance in Conducting Clinical Trial For New Treatments For Brain Cancer

Lotus Pharmaceutical, Hualian Tzu Chi Hospital and EF Biotech signed MOU today regarding the co-development of the combo targeted therapy of Cerebraca wafer and Temozolomide for the treatment of Glioblastoma Multiformis (GBM). Under the agreement, clinical trial of this new treatment for brain cancer will begin in June. Superintendent of Tzu Chi Shinn-Zong Lin, Chairman of EF Biotech Doctor Pei-Wen Chou, and Sales Director of Lotus Pharmaceutical Dino Kuan appeared at the signing press conference today at 2pm.

Read More

Highly experienced management team with a proven track record of achieving high growth and profitability.


News alert

Enter your email to sign up for news alerts